LIFECORE BIOMEDICAL, INC. DE (LFCR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 05-25. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q1 '16: 541M Q2 '16: 548.8M Q3 '16: 540.2M Q4 '16: 541.1M Q1 '17: 514.8M Q2 '17: 484.5M Q3 '17: 483.8M Q4 '17: 469.8M Q1 '18: 476.5M Q2 '18: 488.8M Q3 '18: 504.4M Q4 '18: 524.2M Q1 '19: 533.1M Q2 '19: 535.2M Q3 '19: 545.9M Q4 '19: 557.6M Q1 '20: 571.6M Q2 '20: 589.6M Q3 '20: 587M Q4 '20: 590.4M Q1 '21: 587.3M Q2 '21: 575.6M Q3 '21: 467.4M Q4 '21: 356.2M Q1 '22: 262.1M Q2 '22: 174.7M Q3 '22: 167.4M Q4 '22: 150.6M Q1 '23: 132.7M Q2 '23: 111.1M Q3 '23: 100.2M Q4 '23: 103.3M Q1 '24: 104.1M Q2 '24: 112.4M Q3 '24: 121.5M Q4 '24: 128.3M Q1 '25: 128.4M Q2 '25: 130.9M Q3 '25: 130.3M Q4 '25: 128.9M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Gross Profit TTM

0 30M 60M 90M Q1 '15: 64.2M Q4 '15: 65.4M Q1 '16: 69.2M Q2 '16: 70.8M Q3 '16: 66.8M Q4 '16: 71M Q3 '17: 82.1M Q4 '17: 82.6M Q1 '18: 80.3M Q2 '18: 76.3M Q3 '18: 72.6M Q4 '18: 78.3M Q1 '19: 75.9M Q2 '19: 77.8M Q3 '19: 79.6M Q4 '19: 81M Q1 '20: 80M Q2 '20: 78.6M Q3 '20: 77.1M Q4 '20: 75M Q1 '21: 76M Q2 '21: 81.1M Q3 '21: 75.5M Q4 '21: 66M Q1 '22: 60.1M Q2 '22: 54.2M Q3 '22: 52.6M Q4 '22: 48.4M Q1 '23: 44M Q2 '23: 34.9M Q3 '23: 30.6M Q4 '23: 28M Q1 '24: 24.7M Q2 '24: 29M Q3 '24: 32.4M Q4 '24: 41.9M Q1 '25: 44.5M Q2 '25: 45.6M Q3 '25: 43.6M Q4 '25: 40.3M Q3 '16 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q1 '16: 18.9M Q2 '16: 17.8M Q3 '16: -20.7M Q4 '16: -20.6M Q1 '17: -19.1M Q2 '17: -18.6M Q3 '17: 19.3M Q4 '17: 14.7M Q1 '18: 11.9M Q2 '18: 8M Q3 '18: 7.1M Q4 '18: 13.6M Q1 '19: 10.6M Q2 '19: 11.3M Q3 '19: 11.1M Q4 '19: 5.5M Q1 '20: 1.4M Q2 '20: -4.7M Q3 '20: -22.9M Q4 '20: -25.9M Q1 '21: -34M Q2 '21: -29.4M Q3 '21: -11.9M Q4 '21: -8.8M Q1 '22: 903K Q2 '22: 6.5M Q3 '22: -4.5M Q4 '22: -9.8M Q1 '23: -10.3M Q2 '23: -19.8M Q3 '23: -17.8M Q4 '23: -21.8M Q1 '24: -27.1M Q2 '24: -23.3M Q3 '24: -17.6M Q4 '24: -8.8M Q1 '25: -11.8M Q2 '25: -12.3M Q3 '25: -20.4M Q4 '25: -17.2M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q1 '16: 14.1M Q2 '16: 12.8M Q3 '16: -12.2M Q4 '16: -11.6M Q1 '17: -11.3M Q2 '17: -11.8M Q3 '17: 12.9M Q4 '17: 10.6M Q1 '18: 9.4M Q2 '18: 8.6M Q3 '18: 21.2M Q4 '18: 24.8M Q1 '19: 22.9M Q2 '19: 21.8M Q3 '19: 6.8M Q4 '19: 410K Q1 '20: -4.6M Q2 '20: -10.7M Q3 '20: -23.3M Q4 '20: -38.2M Q1 '21: -44.4M Q2 '21: -51M Q3 '21: -44.9M Q4 '21: -31.1M Q1 '22: -29.6M Q2 '22: -54.8M Q3 '22: -62.4M Q4 '22: -116.4M Q1 '23: -117.8M Q2 '23: -92.1M Q3 '23: -115.5M Q4 '23: -99.6M Q1 '24: -99.4M Q2 '24: -72.3M Q3 '24: -20.2M Q4 '24: 12M Q1 '25: 6.5M Q2 '25: -14.3M Q3 '25: -44.7M Q4 '25: -38.7M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Cost of Revenue TTM

0 200M 400M 600M Q4 '11: 230M Q1 '12: 238.9M Q2 '12: 249.2M Q3 '12: 255.1M Q4 '12: 265.4M Q1 '13: 291.7M Q2 '13: 319.3M Q3 '13: 352.8M Q4 '13: 378.9M Q1 '14: 387.6M Q2 '14: 397.7M Q3 '14: 403.5M Q4 '18: 445.9M Q1 '19: 457.2M Q2 '19: 457.4M Q3 '19: 466.3M Q4 '19: 476.6M Q1 '20: 491.6M Q2 '20: 511M Q3 '20: 509.9M Q4 '23: 75.3M Q1 '24: 79.3M Q2 '24: 83.3M Q3 '24: 89.2M Q4 '24: 86.4M Q1 '25: 83.9M Q2 '25: 85.2M Q3 '25: 86.7M Q4 '25: 88.6M Q4 '11 Q4 '12 Q4 '13 Q4 '18 Q4 '19 Q4 '23 Q4 '24 Q4 '25

Operating Cash Flow TTM

-50M -25M 0 25M 50M 75M Q3 '13: 27.1M Q4 '13: 21.2M Q1 '14: 20.7M Q2 '14: 23.1M Q3 '14: 21.6M Q4 '14: 21M Q1 '15: 20.4M Q4 '15: 26.6M Q1 '16: 20.9M Q2 '16: 25.6M Q3 '16: 19.7M Q4 '16: 21.9M Q1 '17: 33.7M Q2 '17: 39.3M Q3 '17: 61.8M Q4 '17: 53M Q1 '18: 46.4M Q2 '18: 43.1M Q3 '18: 36.7M Q4 '18: 29.6M Q1 '19: 28.3M Q2 '19: 24.6M Q3 '19: 16.9M Q4 '20: -17M Q1 '21: 5.4M Q2 '21: 16.1M Q3 '21: -1.5M Q4 '21: 16.5M Q1 '22: 281K Q2 '22: -5.8M Q3 '22: -16M Q4 '22: -23.1M Q1 '23: -25.1M Q2 '23: -22.6M Q3 '23: -17M Q4 '23: -17.4M Q1 '24: -24.7M Q2 '24: -21M Q3 '24: -10.7M Q4 '25: -205K Q3 '14 Q2 '16 Q3 '17 Q4 '18 Q1 '21 Q2 '22 Q3 '23 Q4 '25

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '12: 4.9M Q4 '12: 16.8M Q1 '13: 17.1M Q2 '13: 19.7M Q3 '13: 21.1M Q4 '13: 12.4M Q1 '14: 9.5M Q2 '14: 9.9M Q3 '14: 7.1M Q4 '14: 6.2M Q1 '15: 5.8M Q4 '15: 9.1M Q1 '16: 4M Q2 '16: -29K Q3 '16: -13.8M Q4 '16: -17.8M Q1 '17: -4.7M Q2 '17: 10.1M Q3 '17: 38.8M Q4 '17: 30M Q1 '18: 19.8M Q2 '18: 15.4M Q3 '18: 2.5M Q4 '18: -4M Q1 '19: -14M Q2 '19: -18.2M Q3 '19: -29.1M Q4 '21: -2.8M Q1 '22: -22.3M Q2 '22: -30.6M Q3 '22: -42.4M Q4 '22: -49.4M Q1 '23: -46.7M Q2 '23: -43M Q3 '23: -39M Q4 '25: -13.6M Q3 '12 Q4 '13 Q1 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '22 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '14: 27.1M Q3 '14: 27.1M Q1 '15: 27.3M Q1 '15: 27.3M Q2 '15: 27.3M Q4 '15: 27.4M Q1 '16: 27.4M Q2 '16: 27.4M Q3 '16: 27.1M Q1 '17: 27.5M Q2 '17: 27.6M Q3 '17: 27.7M Q1 '18: 27.9M Q2 '18: 27.9M Q3 '18: 27.9M Q1 '19: 28M Q2 '19: 27.8M Q3 '19: 29.2M Q1 '20: 29.1M Q2 '20: 29.2M Q3 '20: 29.2M Q1 '21: 29.2M Q2 '21: 29.3M Q3 '21: 29.3M Q1 '22: 29.4M Q2 '22: 29.5M Q3 '22: 29.5M Q1 '23: 29.6M Q2 '23: 29.6M Q3 '23: 30.3M Q1 '24: 30.4M Q2 '24: 36.4M Q3 '24: 36.6M Q1 '25: 30.9M Q2 '25: 34.4M Q3 '25: 37M Q4 '25: 37M Q2 '26: 37.4M Q4 '26: 37.5M Q1 '27: 37.6M Q2 '15 Q1 '17 Q3 '18 Q2 '20 Q1 '22 Q3 '23 Q2 '25 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q1 '16: 0.52 Q2 '16: 0.47 Q3 '16: -0.45 Q4 '16: -0.43 Q1 '17: -0.42 Q2 '17: -0.44 Q3 '17: 0.47 Q4 '17: 0.39 Q1 '18: 0.35 Q2 '18: 0.32 Q3 '18: 0.76 Q4 '18: 0.89 Q1 '19: 0.82 Q2 '19: 0.78 Q3 '19: 0.25 Q4 '19: 0.01 Q1 '20: -0.16 Q2 '20: -0.37 Q3 '20: -0.80 Q4 '20: -1.30 Q1 '21: -1.52 Q2 '21: -1.74 Q3 '21: -1.54 Q4 '21: -1.06 Q1 '22: -1.00 Q2 '22: -1.85 Q3 '22: -2.11 Q4 '22: -3.95 Q1 '23: -4.00 Q2 '23: -3.13 Q3 '23: -3.88 Q4 '23: -3.32 Q1 '24: -3.30 Q2 '24: -2.48 Q3 '24: -0.86 Q4 '24: 0.33 Q1 '25: 0.15 Q2 '25: -0.49 Q3 '25: -1.33 Q4 '25: -1.26 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.